The role of the P-53 gene and the P-53 protein in non-Hodgkin malignant lymphomas

The role of the P-53 gene and the P-53 Protein in the oncogenesis of non-Hodgkin malignant lymphomas

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN12539707

Enrollment

Registered

2022-11-12

Start date

2016-11-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin malignant lymphomas Cancer

Interventions

Complete physical examination: In patients diagnosed with CLL-B, symptoms such as frequent cough, night sweats, and retrosternal pain were evaluated. Clinical examination and ultrasound revealed lymph

Format: Purified product: Monoclonal antibody clone: Isotype DO-1: IgG2a. The antibody is suitable for the techniques: ICC / IF and ELISA. The research antibody PAb 1620 has been reported to be specif

solid support: 96-well mi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with CLL-B who were hospitalized in the Hematology departments of the Targu Mures Oncology Institute and Cluj-Napoca between November 2016 and September 2019 2. CLL with> 5000 lymphocytes in absolute value, present at the cytological examination of the blood smear, from the peripheral blood or LLC with less than 10% prolymphocytes based on the peripheral blood smears May-Grunwald Giemsa, stained

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
P-53 isoform protein concentration measured using sandwich ELISA colorimetric quantitative method at a single timepoint	—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Romania

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 5, 2026